Post by stcks on Jan 22, 2018 2:17:58 GMT
Sanofi SA is nearing a deal to buy hemophilia drugmaker Bioverativ Inc. for more than $11.5 billion as the French drugmaker looks set to clinch a big deal while it braces for generic competition for its top-selling product.
A deal, which could be announced as soon as Monday, would value the former Biogen Inc. unit at $105 a share, according to people
www.wsj.com/articles/sanofi-nears-deal-to-buy-hemophilia-drugmaker-bioverativ-for-more-than-11-5-billion-1516584141
A deal, which could be announced as soon as Monday, would value the former Biogen Inc. unit at $105 a share, according to people
www.wsj.com/articles/sanofi-nears-deal-to-buy-hemophilia-drugmaker-bioverativ-for-more-than-11-5-billion-1516584141
